On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for paediatric low-grade glioma.
The publication was widely covered as a procedural milestone. It is also a concrete case study in the relationship between clinical evidence quality and market access risk — and in where structured, pre-decision risk assessment adds value.
What the JCA actually found
The assessment covered eight patient population and comparator combinations. Only one had any comparative data.
For the full claimed indication, no head-to-head evidence was available. The single comparison included — tovorafenib versus dabrafenib plus trametinib in a BRAF V600E subpopulation — relied on an unanchored indirect comparison with an effective sample size as low as 5.81. No overall survival data. No comparative quality-of-life results. The JCA assessors also identified errors in the manufacturer’s sensitivity analysis and excluded it from the report entirely.
The phrase “major uncertainties” appears in every result table the JCA published.
This is not a failure of the process. It is the process functioning correctly — surfacing, in a structured and transparent way, the evidentiary limitations that will now define the access challenge across 27 national markets.
What MARA had assessed before the publication
In May 2026, MARA Rating assigned tovorafenib a B+ (Very Weak), with a Market Access Score of 55/100 and Low confidence.
The primary drivers: Clinical Effectiveness rated Moderate, with the absence of comparative data identified as the central constraint. Cost-Effectiveness rated Weak — no published economic analysis existed. HRQoL rated Weak — only exploratory, uncontrolled abstract-level data available, with no utility data suitable for QALY modelling.
The JCA confirmed each of these assessments directly.
One domain diverged. MARA rated safety as supportive based on the FDA label profile. The JCA’s indirect comparison flagged elevated severe adverse event rates for tovorafenib versus the active comparator. That comparison carries major methodological caveats, but it is a finding the rating should account for going forward.
What the JCA does not resolve
The JCA is now the shared clinical foundation for every national pricing and reimbursement process across the EU. That is its purpose and its value.
But it answers a clinical question. National payers will ask a different one.
G-BA will evaluate incremental benefit against a standard of care — using evidence the JCA described as methodologically limited. NICE will face a drug with no cost-effectiveness data and a clinical profile that, in comparable assets, has been associated with an 82% rejection rate in the MARA historical dataset. HAS will assess medical benefit using a comparative evidence base that produced no QoL outcomes and no survival data.
The JCA does not determine those outcomes. It makes the evidence constraints that will shape them explicit and shared.
The B+ signal was not a prediction about the JCA. It was a calibrated assessment of the evidence profile national payers would encounter — derived from 538 historical decisions across G-BA, NICE, HAS, and ICER. The JCA confirmed the profile. The access risk it signals remains unchanged.
MARA Rating calibrates market access risk before HTA decisions are published, grounded in historical payer behaviour across major markets.
Explore the rating here: